Verve Therapeutics has started dosing patients ... in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing.

In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique ...

Verve Therapeutics (NASDAQ:VERV) just today announced that it had received IND clearance from the FDA in the United States in order to advance its 2nd gene editing candidate VERVE-102 for the ...

Most previous CRISPR trials have focused on knocking ... given the setbacks seen in a study of another base editing treatment from Verve Therapeutics last year, which forced the company to restart ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

Beam Therapeutics Inc.’s BEAM share price has dipped by 11.15%, which has investors questioning if this is right time to buy.

BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31 ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22.

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against other best gene-editing ...